1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Retinitis Pigmentosa - Pipeline Review, H1 2020, provides an overview of the Retinitis Pigmentosa (Ophthalmology) pipeline landscape.
Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance and x-linked inheritance.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Retinitis Pigmentosa - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Retinitis Pigmentosa (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 17, 1, 1, 37 and 14 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 11 molecules, respectively.
Retinitis Pigmentosa (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Retinitis Pigmentosa (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Retinitis Pigmentosa (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Retinitis Pigmentosa (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Retinitis Pigmentosa (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Retinitis Pigmentosa (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Retinitis Pigmentosa (Retinitis) - Overview
- Retinitis Pigmentosa (Retinitis) - Therapeutics Development
- Retinitis Pigmentosa (Retinitis) - Therapeutics Assessment
- Retinitis Pigmentosa (Retinitis) - Companies Involved in Therapeutics Development
- Retinitis Pigmentosa (Retinitis) - Drug Profiles
- Retinitis Pigmentosa (Retinitis) - Dormant Projects
- Retinitis Pigmentosa (Retinitis) - Discontinued Products
- Retinitis Pigmentosa (Retinitis) - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Retinitis Pigmentosa (Retinitis), H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Retinitis Pigmentosa (Retinitis) - Pipeline by 4D Molecular Therapeutics Inc, H1 2020
- Retinitis Pigmentosa (Retinitis) - Pipeline by Allegro Ophthalmics LLC, H1 2020
- Retinitis Pigmentosa (Retinitis) - Pipeline by Allergan Ltd, H1 2020
- Retinitis Pigmentosa (Retinitis) - Pipeline by Alpine Biotherapeutics Corp, H1 2020
- Retinitis Pigmentosa (Retinitis) - Pipeline by Amgen Inc, H1 2020
- Retinitis Pigmentosa (Retinitis) - Pipeline by Ankar Pharma SL, H1 2020
- Retinitis Pigmentosa (Retinitis) - Pipeline by Applied Genetic Technologies Corp, H1 2020
- Retinitis Pigmentosa (Retinitis) - Pipeline by Biogen Inc, H1 2020
- Retinitis Pigmentosa (Retinitis) - Pipeline by Brighton Biotech Inc, H1 2020
- Retinitis Pigmentosa (Retinitis) - Pipeline by Casebia Therapeutics, H1 2020
- Retinitis Pigmentosa (Retinitis) - Pipeline by Copernicus Therapeutics Inc, H1 2020
- Retinitis Pigmentosa (Retinitis) - Pipeline by Dompe Farmaceutici SpA, H1 2020
- Retinitis Pigmentosa (Retinitis) - Pipeline by DTx Pharma Inc, H1 2020
- Retinitis Pigmentosa (Retinitis) - Pipeline by Editas Medicine Inc, H1 2020
- Retinitis Pigmentosa (Retinitis) - Dormant Projects, H1 2020
- Retinitis Pigmentosa (Retinitis) - Discontinued Products, H1 2020
List of Figures
- Number of Products under Development for Retinitis Pigmentosa (Retinitis), H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4D Molecular Therapeutics Inc
- Allegro Ophthalmics LLC
- Allergan Ltd
- Alpine Biotherapeutics Corp
- Amgen Inc
- Ankar Pharma SL
- Applied Genetic Technologies Corp
- Biogen Inc
- Brighton Biotech Inc
- Casebia Therapeutics
- Copernicus Therapeutics Inc
- Dompe Farmaceutici SpA
- DTx Pharma Inc
- Editas Medicine Inc
- Emerald Organic Products Inc
- Endogena Therapeutics Inc
- EyePoint Pharmaceuticals Inc
- Eyestem Research Pvt Ltd
- Eyevensys SAS
- GenSight Biologics SA
- Grupo Ferrer Internacional SA
- Horama SA
- ID Pharma Co Ltd
- IVERIC bio Inc
- jCyte Inc
- Kubota Vision Inc
- Kyoto Drug Discovery & Development Co Ltd
- Lineage Cell Therapeutics Inc
- MeiraGTx Holdings Plc
- MimeTech Srl
- Miragen Therapeutics Inc
- Mireca Medicines GmbH
- NanoScope Technologies LLC
- Nanovector srl
- Novartis AG
- Ocugen Inc
- OiDE OptoEye Inc
- OliX Pharmaceuticals Inc
- ONL Therapeutics Inc
- OptiKira LLC
- Oxford BioMedica Plc
- Precision Biosciences Inc
- Profarma
- ProQR Therapeutics NV
- PYCTX Ltd
- Recursion Pharmaceuticals Inc
- ReNeuron Group Plc
- Retinagenix LLC
- Rznomics Inc
- SanBio Company Limited
- SparingVision SAS
- Staidson BioPharma Inc
- Sumitomo Dainippon Pharma Co Ltd
- Wave Life Sciences Ltd
